Cosmo Pharmaceuticals NV
SIX:COPN

Watchlist Manager
Cosmo Pharmaceuticals NV Logo
Cosmo Pharmaceuticals NV
SIX:COPN
Watchlist
Price: 65 CHF Market Closed
Market Cap: 1B CHF
Have any thoughts about
Cosmo Pharmaceuticals NV?
Write Note

Cosmo Pharmaceuticals NV
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Cosmo Pharmaceuticals NV
Income from Continuing Operations Peer Comparison

Comparables:
PRGO
JAZZ
AVDL
G
GHRS
OVB

Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Cosmo Pharmaceuticals NV
SIX:COPN
Income from Continuing Operations
€75.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-1%
Perrigo Company PLC
NYSE:PRGO
Income from Continuing Operations
-$146.9m
CAGR 3-Years
12%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
Income from Continuing Operations
$465.3m
CAGR 3-Years
N/A
CAGR 5-Years
-5%
CAGR 10-Years
31%
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Income from Continuing Operations
-$106.2m
CAGR 3-Years
-24%
CAGR 5-Years
-1%
CAGR 10-Years
-7%
G
GH Research PLC
NASDAQ:GHRS
Income from Continuing Operations
-$35.6m
CAGR 3-Years
-329%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Ovoca Bio PLC
LSE:OVB
Income from Continuing Operations
-€4m
CAGR 3-Years
-5%
CAGR 5-Years
-15%
CAGR 10-Years
7%

See Also

What is Cosmo Pharmaceuticals NV's Income from Continuing Operations?
Income from Continuing Operations
75.9m EUR

Based on the financial report for Jun 30, 2024, Cosmo Pharmaceuticals NV's Income from Continuing Operations amounts to 75.9m EUR.

What is Cosmo Pharmaceuticals NV's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
-1%

Over the last year, the Income from Continuing Operations growth was 584%.

Back to Top